SYNTOCINON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Syntocinon, and when can generic versions of Syntocinon launch?
Syntocinon is a drug marketed by Novartis and Rtrx and is included in two NDAs.
The generic ingredient in SYNTOCINON is oxytocin. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the oxytocin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Syntocinon
A generic version of SYNTOCINON was approved as oxytocin by HIKMA on January 10th, 2007.
Summary for SYNTOCINON
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 127 |
Patent Applications: | 3,859 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SYNTOCINON at DailyMed |
Recent Clinical Trials for SYNTOCINON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 4 |
The University of Hong Kong | Phase 4 |
University of California, San Francisco | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for SYNTOCINON
US Patents and Regulatory Information for SYNTOCINON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SYNTOCINON | oxytocin | INJECTABLE;INJECTION | 018245-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Rtrx | SYNTOCINON | oxytocin | SOLUTION;NASAL | 012285-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |